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Metabolic flexibility is the capacity of a system to adjust fuel (primarily glucose and fatty acids) oxidation based on
nutrient availability. The ability to alter substrate oxidation in response to nutritional state depends on the
genetically influenced balance between oxidation and storage capacities. Competition between fatty acids and
glucose for oxidation occurs at the level of the pyruvate dehydrogenase complex (PDC). The PDC is normally active
in most tissues in the fed state, and suppressing PDC activity by pyruvate dehydrogenase (PDH) kinase (PDK) is
crucial to maintain energy homeostasis under some extreme nutritional conditions in mammals. Conversely,
inappropriate suppression of PDC activity might promote the development of metabolic diseases. This review
summarizes PDKs’ pivotal role in control of metabolic flexibility under various nutrient conditions and in different
tissues, with emphasis on the best characterized PDK4. Understanding the regulation of PDC and PDKs and their
roles in energy homeostasis could be beneficial to alleviate metabolic inflexibility and to provide possible therapies
for metabolic diseases, including type 2 diabetes (T2D).
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Maintaining a balance between energy demand and sup-
ply is critical for health. Glucose and lipids (fatty acids
and ketone bodies), as sources of cellular energy, can
compete and interact with each other [1]. The capacity
for an organism to adapt fuel oxidation to fuel availabil-
ity, that is, to preferentially utilize carbohydrate and lipid
fuels and to be able to rapidly switch between them is
termed metabolic flexibility [2,3]. The failure to match
fuel oxidation to changes in nutrient availability is often
accompanied by symptoms such as insulin resistance,
ectopic lipid accumulation and mitochondrial dysfunc-
tion [3,4]. Thus, metabolic inflexibility is tightly related
to a series of syndromes such as type 2 diabetes (T2D),
obesity, cardiovascular disease and metabolic syndrome.
One of the major enzymes responsible for metabolic
flexibility in mammals is the pyruvate dehydrogenase
complex (PDC), a mitochondrial multi-enzyme complex
that catalyzes the oxidative decarboxylation of pyruvate
[5]. PDC controls the conversion of pyruvate, Coenzyme* Correspondence: egilbert@vt.edu
1Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA, USA
33200 Litton-Reaves, Animal & Poultry Sciences Department, Virginia Tech,
Blacksburg, VA 24061-0306, USA
Full list of author information is available at the end of the article
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.A (CoA) and NAD+ into acetyl-CoA, NADH and CO2,
and thus links fatty acid metabolism, glucose metabolism
and the tricarboxylic acid (TCA) cycle [6]. The CoA-
activated two-carbon unit produced by the catabolism of
pyruvate can be condensed with oxaloacetate in the first
reaction of the TCA cycle, or used for fatty acid and
cholesterol synthesis [7]. Pyruvate may also be conserved
for gluconeogenesis in liver and kidney [8]. Thus, the
PDC occupies a central position in cellular energy me-
tabolism (Figure 1).
PDC is more active in the healthy and well-fed state.
However, suppression of PDC is crucial for glucose syn-
thesis when glucose is scarce [9]. The inactivation of
PDC activity is catalyzed by four highly specific pyruvate
dehydrogenase (PDH) kinase (PDK) isozymes that can
phosphorylate specific serine residues within the α subunit
of the E1 enzyme in the PDC [5,10]. Of all the known
isozymes, PDK2 and PDK4 are the most widely distrib-
uted and are highly expressed in heart, liver and kidney
in humans and rodents. PDK4 is also abundant in pan-
creatic islets and in skeletal muscles that have high glu-
cose utilization and fatty acid oxidation rates. PDK1
and PDK3 have rather limited tissue distribution [11].
The PDKs activities can be regulated by different levelsLtd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 PDC and PDKs occupy central positions in cellular energy metabolism. Fatty acid and glucose compete with each other for
oxidation at the level of the PDC in mammals. PDC catalyzes the oxidative decarboxylation of pyruvate to form acetyl-CoA and thus links glucose
metabolism and fatty acid metabolism. PDC can be phosphorylated by PDKs, which can be regulated by mitochondrial acetyl-CoA, NADH, pyruvate,
ATP and nuclear transcription factors. ERRα: Estrogen related receptor α; FoxO: Forkhead box protein O; NEFA: Non-esterified fatty acid; PDC: Pyruvate
dehydrogenase complex; PDKs: Pyruvate dehydrogenase kinases; PGC1α: PPARγ co-activator 1α; PPARs: Peroxisome proliferator-activated receptors; TG:
Triglyceride; TCA: Tricarboxylic acid.
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various conditions and in different tissues (Figure 2).
Thus the PDC can manage the utilization and storage
of fuels to fulfill metabolic flexibility in response to the
environment.
This review summarizes the recent studies on PDKs
pivotal role in controlling metabolic flexibility, a recent
concept in cellular energy metabolism, under various
nutritional conditions (energy deprivation, high fat diet
consumption, exercise and disease) in diverse tissues
(skeletal muscle, liver, white adipose tissue, heart, pan-
creatic islets and nervous system), with emphasis on the
best characterized PDK4. Understanding the regulation
of PDKs in different tissues and their roles in energy
homeostasis will be beneficial for treatment of different
kinds of metabolic diseases.
PDK and metabolic flexibility in skeletal muscle
As quantitatively the largest organ in the body, skeletal
muscle accounts for 30% to 40% of the metabolic rate in
adults in the resting state. Contributing to 80% of
insulin-stimulated glucose uptake, it is a major site for
glucose oxidation and fatty acid metabolism [12]. The
skeletal muscle exhibits remarkable metabolic flexibility
in fuel usage in response to various metabolic challenges
such as energy deprivation and changes in diet compos-
ition. In lean healthy individuals, under insulin stimula-
tion, skeletal muscle is able to switch from predominantly
lipid oxidation and high rates of fatty acid uptake to thesuppression of lipid catabolism and elevated glucose up-
take, oxidation and storage [13]. However, obese and T2D
patients manifest greater rates of lipid oxidation in skeletal
muscle and are relatively insulin resistant, resulting in
metabolic inflexibility [13].
Energy deprivation
During energy deprivation, glucose is scarce and long-
chain fatty acid oxidation is used to meet cellular energy
requirements. Reduced food intake and lowered insulin
concentrations decrease glucose utilization to conserve
glucose [6]. Mammalian PDC activity is suppressed by
PDK’s hyper-phosphorylation, limiting the conversion of
pyruvate to acetyl-CoA in skeletal muscle [11]. With less
acetyl-CoA available, the synthesis of malonyl-CoA, an
inhibitor of fatty acid oxidation, is reduced [14]. As a re-
sult, fatty acid oxidation is both forced and facilitated by
up-regulation of PDK4 [15]. Forty eight hours of fasting
in rats (complete food withdrawal) was associated with a
3–4 fold increase in PDK4 protein and mRNA in gastro-
cnemius muscle, with no effects on PDK2 expression
[16]. Forty eight hour-fasted PDK4 knock-out mice
exhibited lowered blood glucose, elevated serum non-
esterified fatty acids and greater PDC activity in gastro-
cnemius muscle [17], consistent with the lower rates of
fatty acid oxidation and increased rates of glucose and
pyruvate oxidation. However, energy deprivation led to a
decrease rather than increase in PDK2 activity in gastro-
cnemius muscle in PDK4 knock-out mice [17]. This
Figure 2 Transcriptional regulation pathways of PDK4 in different tissues under various nutritional states. Inactivation of PDC by
up-regulation of PDK4 can switch glucose catabolism to fatty acid utilization. There are different transcriptional regulation pathways in skeletal muscle,
liver, white adipose tissue and heart under various nutritional conditions (energy deprivation, high fat diet consumption, exercise, diseases, drugs).
Akt/PKB: protein kinase B; AMPK: 5’-AMP-activated protein kinase; CD36: Cluster of differentiation 36; C/EBPβ: CCAAT/enhancer-binding protein β; eIF4E:
Eukaryotic initiation factor 4E; ERRα: Estrogen related receptor α; FAT: Fatty acid transporter; FoxO1: Forkhead box protein O1; LXR: Liver X receptor;
MAPK: p38 mitogen-activated protein kinase; PDC: Pyruvate dehydrogenase complex; PDK4: Pyruvate dehydrogenase kinase 4; PGC1α: PPARγ
co-activator 1α; PPARs: Peroxisome proliferator-activated receptors; SHP: Small heterodimer partner; STAT5: Signal transducer and activator of
transcription 5.
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loss of function of PDK4 in response to fasting. Refeed-
ing the fasted wild-type rats for 48 h reduced PDK4
mRNA to a level comparable to the control group [16].
The acetyl-CoA and NADH produced by fatty acid
oxidation stimulated PDK activity in skeletal muscle
[11]. There was also a selective induction of forkhead
box O1 (FoxO1) and forkhead box O3 (FoxO3) tran-
scripts in gastrocnemius muscle in mice after 48 h of
food withdrawal [18], indicating the involvement of the
FoxO in up-regulation of PDK4 in response to short-
term changes in nutritional state. PDK4, interacting with
fatty acid transporter/cluster of differentiation 36 (FAT/
CD36, major fatty acid uptake proteins in muscle),
peroxisome-proliferator activated receptor δ/β (PPARδ/
β, fatty acid activated nuclear receptor) and FoxO1, pro-
vides a framework for regulating muscle fuel preference
in response to fasting [19]. During energy deprivation,
CD36-facilitated fatty acid flux activates PPARδ/β, which
coordinately increases the expression of FoxO1 and
PDK4 to inhibit glucose oxidation. The fatty acid flux
and decreased insulin concentrations are associated with
down-regulation of protein kinase B (Akt/PKB), leading
to FoxO1 activation [20]. Since FoxO1 also recruits
CD36 to the plasma membrane and induces lipoprotein
lipase, all of these enhance fatty acid utilization in skel-
etal muscle [19]. The novel liver X receptor (LXR)-
PPARα metabolostatic signaling axis was also reportedto be involved in the muscle energy deprivation response
[21,22]. The activation of LXR augmented PPARα signal-
ing to increase fasting-induced up-regulation of PDK4
expression, thus enhancing fatty acid oxidation and de-
creasing glucose catabolism in skeletal muscle [21,22].
Long-term high fat diet consumption
Long-term consumption of a high-saturated fat diet may
cause hyperglycemia, hyperinsulinaemia, glucose intoler-
ance and obesity. The administration of a diet high in
saturated fats for 4 weeks to rats significantly increased
PDK2 and PDK4 protein expression in both fast-twitch
white muscle fiber sub-types (anterior tibialis) and slow-
twitch red muscle fiber sub-types (soleus) in rats [23].
The slow-twitch red muscle fiber is rich in mitochondria
and myoglobin and relies on aerobic metabolism of
carbohydrate and lipid fuels. In soleus, the relative in-
crease in PDK4 expression was also linked to a more
than 7 fold increase in pyruvate concentration and a
50% reduction in PDC activity compared to that in an-
terior tibialis [23], indicating greater loss of PDK sensi-
tivity due to pyruvate inhibition in fast-twitch muscle
compared to slow-twitch muscle. Consumption of a high
fat diet leads to the use of lipid-derived fuels as respira-
tory substrates in muscle, in part modulated by the up-
regulation in PDK activity. The enhanced fatty acid oxi-
dation after feeding high fat diets in slow-twitch muscle
is mainly attributed to the up-regulation of PDK4.
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was also observed [23], suggestive of a possible coordin-
ate regulation between PDK2 and PDK4 in white muscle
fiber sub-types.
PDK4 deficiency leads to inhibition of fatty acid oxida-
tion and increases in glucose oxidation due to greater
PDC activity, which increases the conversion of pyru-
vate into acetyl-CoA. With more acetyl CoA available to
synthesize malonyl-CoA, an inhibitor of fatty acid oxi-
dation, the rate of fatty acid oxidation decreases due to
a direct feedback loop [14]. However, feeding high-fat
diets in the long term neither promotes further ectopic
fat accumulation nor worsens insulin resistance [24,25].
After feeding a high-saturated fat diet for 32 weeks in
PDK4 knockout mice, the PDK4 deficient mice also de-
veloped hyperinsulinaemia, but less fat accumulation in
skeletal muscle and better glucose tolerance as com-
pared to the wild-type mice [25]. The fatty acid synthase
activity was also lower, suggesting that the absence of
PDK4 may alter signaling components involved in regu-
lation of lipid metabolism [25].
Up-regulation of the orphan nuclear receptor estro-
gen related receptor α (ERRα) mRNA and protein was
found in mice after chronic consumption of a high-fat
diet [26]. It has been suggested that PPARγ coactivator
1α (PGC1α) can regulate glucose catabolism and mi-
tochondrial oxidative pathways by increasing PDK4 ac-
tivity via a PGC1α/ERRα dependent pathway in skeletal
muscle [27,28]. ERRα can recruit PGC1α to combine to
the PDK4 promoter and regulate PDK4 transcription,
which is independent of FoxO1 and PPARs [29]. The
negative regulation of PDC activity by PDK4 inhibits
the entry of pyruvate into the TCA cycle and subse-
quently blunts cellular glucose oxidation in response to
high-fat feeding [26]. Thus PGC1α/ERRα has a key role
in high fat diet induced PDK4 up-regulation and meta-
bolic flexibility in skeletal muscle.
Exercise
It was found that PDC activation during low to moderate-
intensity muscle contraction was ~2 fold higher in PDK4
knockout mice than in wild-type mice during exercise, re-
gardless of the intensity [30]. PDK4 mRNA was markedly
increased during prolonged exercise and after both short-
term high-intensity and prolonged low-intensity exercise
in skeletal muscle in mice [31]. The inactivation of PDC
in response to both slow-twitch and fast-twitch muscle
contraction through up-regulated PDK4 can limit the
entry of glycolytic products into the mitochondria for oxi-
dation. The recovery period after exercise also highlights
the high metabolic priority of glycogen replenishing to re-
establishing the energy homeostasis in skeletal muscle
[31]. High fat diet consumption for 18 weeks followed by
12 h exercise also elevated PDK4 expression in skeletalmuscle in mice [32], leading to reduced PDC activity and
less carbohydrate oxidation. FoxO1 was suggested to be a
possible transcription factor related to this change. FoxO1
can sense changes in availability of free fatty acids, and
relay this message downstream by modulating transcrip-
tion of PDK4 [32]. Un-phosphorylated FoxO1 resides in
the nucleus where it can activate transcription of genes
that contain insulin response elements. Phosphorylation
of FoxO1 through the Akt/PKB pathway leads to nuclear
exclusion and destruction [20]. PGC1α also played signifi-
cant roles in skeletal muscle in response to exercise ac-
cording to research on horses [33]. PGC1α regulated
glucose oxidation while increasing mitochondrial respir-
ation and fatty acid oxidation during post-exercise recov-
ery in Thoroughbred horses [33].
In addition to exercising muscle, during acute endur-
ance exercise in the one-leg cycling model, the resting
muscle also showed increased PDK4 expression, likely me-
diated by elevation in circulating free fatty acids, ligands of
PPARs, and up-regulation of PPAR pathways [34].
Insulin resistance and diabetes
Insulin resistance is mostly characterized as a limited re-
sponse to stimulated glucose metabolism in skeletal muscle.
Also the resistance to suppression of lipid utilization under
insulin resistance impaired the capacity to switch between
fuels, leading to metabolic inflexibility [13]. This is very
common for obese and T2D patients in the insulin simu-
lated condition. Kim et. al induced acute insulin resistance
by constant infusion of Intralipid (a fat emulsion) and lac-
tate for 5 h in rats, resulting in 2 to 3 fold higher PDK4
expression in muscle following insulin infusion [35], indi-
cating the impaired ability of insulin to suppress PDK4.
The Intralipid and lactate infusion also decreased the
phosphorylation of Akt/PKB and FoxO1, illustrating the
impaired insulin signaling [35]. A more recent clinical re-
search study showed that growth hormone (GH) can pro-
mote lipolysis and reduce insulin sensitivity in human
subjects. This was associated with up-regulation of PDK4
mRNA and decreased active PDC, similar to what is ob-
served during fasting [36]. The research on T2D patients
muscle biopsies showed that both PDK2 and PDK4
mRNA were increased in comparison to healthy volun-
teers after overnight fasting [37], which was consistent
with the insulin resistance and metabolic inflexibility of
T2D patients. Furthermore, methylation status of cyto-
sines in the +160 and +446 region of the PDK4 pro-
moter was reduced in T2D patients, suggesting that
epigenetic modification of mitochondrial genes are in-
volved in regulating substrate switching [37]. However,
as one of the transcription factors that regulates ex-
pression of PDK4, the PGC1α promoter was reported
to be hyper-methylated in skeletal muscle of T2D sub-
jects [38] and after overfeeding fat to low birth weight
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patterns associated with metabolic disease may be pro-
moter specific [37].
Therapeutic interventions have been used to reduce
PDK4 expression in diabetes. Beyond insulin, several
PDK4 inhibitors were utilized to promote glucose dis-
posal in animal models. Initial studies showed encour-
aging results with oral administration of dichloroacetate
(DCA), but this compound is a weak PDK inhibitor and
toxic [40]. More recently, the potent orally administrated
drugs such as PDK inhibitors produced by Novartis and
AstraZeneca usually include amides of trifluoro-2-hydroxy-
2-methylpropionic acid [41]. All of these inhibitors, in-
cluding the PDK2 inhibitor Nov3r and AZD7545, bind
at the lipoyl group binding site of PDK and effectively
increase PDC activity [41]. Many drugs target the PDK
activity in most peripheral tissues, like DCA [41], but
some drugs have better efficacy in specific tissues. For ex-
ample, AZD7545 elevated PDC activity more effectively in
liver than in skeletal muscle and heart and with the loss of
efficacy in skeletal muscle of fasted animals [42].
PDK and metabolic flexibility in liver
One of the primary functions of liver is to regulate the sup-
ply of glucose and other metabolic fuels to provide energy
to other tissues [20]. The body can balance the blood glu-
cose levels through balancing glucose production and stor-
age in liver and in kidney, and regulating its utilization in
peripheral tissues. Under fasting conditions, the liver ini-
tially provides glucose from glycogenolysis, the breakdown
of liver glycogen stores. With prolonged energy deprivation,
the primary glucose source is gluconeogenesis, the synthe-
sis of glucose from non-carbohydrate precursors such as
glycerol, lactate and the amino acid alanine [20]. Inactiva-
tion of PDC by PDKs can inhibit conversion of pyruvate to
acetyl-CoA, resulting in a shift of pyruvate to the TCA cycle
or fatty acid synthesis toward gluconeogenesis [43].
Fasting for 48 h did not alter PDC activity in the liver
of PDK4 knockout mice, but intermediates of the gluco-
neogenic pathway (glucose-6-phosphate, fructose-1,6-
bisphosphate, pyruvate, lactate and citrate) were lower
[17], indicating a reduced rate of gluconeogenesis and
glycolysis. Growth hormone (GH) can increase hepatic
PDK4 expression in liver in wild-type mice during fasting
through the activation of signal transducer and activator
of transcription 5 (STAT5), leading to inhibition of PDC
activity, conserving substrates for gluconeogenesis [44].
Metformin, a commonly prescribed drug for T2D, can
inhibit GH-induced PDK4 expression via a 5’-AMP-acti-
vated protein kinase - small heterodimer partner (AMPK-
SHP) dependent pathway to inhibit the combination of
STAT5 to the PDK4 promoter [44].
Hepatic expression of the PDK4 and PDK2, and PDC
activity were not affected in wild-type mice fed a high-fatdiet for 18 weeks. [24]. High-fat diet feeding induced hep-
atic steatosis, a condition that occurs when fat accumula-
tion exceeds the oxidation rate [45]. This situation was
prevented in PDK4 knockout mice that consumed a high-
saturated fat diet for 32 weeks [25]. This can be explained
in part by the altered PGC1α activity in the liver. PGC1α
controls expression of gluconeogenic enzymes such as
phosphoenolpyruvate carboxykinase (PEPCK). Knocking
out PDK4 could lead to higher levels of PGC1α, consistent
with greater activity of PEPCK and a lower capacity for de
novo fatty acid synthesis [25]. PPARα also showed coordi-
nated regulation with PGC1α in hepatic steatosis, which
was demonstrated by the enhanced beneficial effects of clo-
fibric acid, a PPARα agonist, on fatty acid accumulation in
PDK4 knockout mice [46]. In contrast to skeletal muscle,
FAT/CD36, key enzymes for fatty acid transport, were not
involved in the reduced fat accumulation in liver [25].
Under diabetic conditions, expression of the PDK
genes, particularly PDK4, are significantly elevated in the
liver, which could help explain the increased rates of glu-
coneogenesis [47], and the beneficial effects of metfor-
min. Research on the diabetic mice model that is
deficient in hepatic insulin receptor substrates 1 and 2
(IRS 1/2) revealed that both knockdown and knockout
of the PDK4 gene led to improvement of glycemic con-
trol and glucose tolerance. PDK4 was more efficient in
regulating metabolic flexibility than PDK2 in liver [47].
Combined with the results from the other studies, it
seems that PDK2 mainly regulates glucose utilization
whereas PDK4 may be involved in both system glucose
metabolism and hepatic gluconeogenesis.
Thyroid hormone (T3) controls multiple aspects of
hepatic energy metabolic processes, such as fatty acid
oxidation, lipogenesis and glucose oxidation. Experimen-
tal hyperthyroidism can induce PDK4 expression in the
liver [48,49], skeletal muscle [50] and heart [51], leading
to inhibition of PDC activity. Two binding sites for thy-
roid hormone receptor β were identified in the promoter
of the rat PDK4 gene [52]. Besides functioning as a T3
co-activator, PGC1α can also enhance the T3 induction
of hepatic PDK4 expression in rats [52]. The CCAAT/
enhancer-binding protein β (C/EBPβ), as a transcription
factor for genes encoding gluconeogenic enzymes such
as PEPCK, also stimulates hepatic PDK4 expression in
rats through two C/EBPβ-response elements in the
PDK4 promoter and also participates in the T3 induction
of PDK4 transcription [53].
PDK4 and metabolic flexibility in white adipose tissue
Compared to the skeletal muscle and liver, relatively little
research is reported on metabolic flexibility in white adi-
pose tissues (WAT). WAT is a crucial organ for a fatty acid
metabolic process referred as adipocyte glyceroneogenesis.
This pathway uses pyruvate, alanine, glutamine or any
Zhang et al. Nutrition & Metabolism 2014, 11:10 Page 6 of 9
http://www.nutritionandmetabolism.com/content/11/1/10substances from the TCA cycle as precursors to synthesize
dihydroxyacetone phosphate (DHAP) and finally to pro-
duce glycerol-3-phosphate (G3P) for triacylglycerol (TAG)
synthesis [54]. PDC is linked to this process and suppres-
sion of PDC allows increased use of lactate and pyruvate
for glyceroneogenesis [55].
As an activator of glyceroneogenesis, thiazolidinediones
(TZD) increased PDK4 mRNA expression in subcutane-
ous, periepididymal and retroperitoneal WAT depots in
fa/fa Zucker rats, a genetic obese, insulin resistant model,
while PDK2 mRNA was not affected, indicating the vital
role of PDK4 in glyceroneogenesis. TZD-induced PDK4
expression was tissue-specific because liver and muscle
did not respond to such a treatment [56]. Similar results
were observed for 3 T3-F442A adipocytes in vitro, using
PDK4 inhibitors, DCA and leelamine, and PDK4 siRNA.
Both 500 μmol/L DCA and 50 μmol/L leelamine inhibited
pyruvate incorporation into triglycerides. Incorporation
of [1-14C] pyruvate into lipids was reduced 40% after
transfection of adipocytes with PDK4 siRNA [56]. PPARγ
is a nuclear receptor regulated by the insulin-sensitizing
TZDs. PDK4 is an indirect target of PPARγ. Thus the
regulation of PDK4 by TZD in WAT tightly relates to
PPARγ [57].
Apart from TZD, acute epinephrine treatment also in-
creased PDK4 mRNA through p38 mitogen-activated
protein kinase (MAPK) and AMPK pathways in cultured
adipocytes [58] and in epididymal WAT depots in obese,
insulin resistant rat models that were induced by high fat
diets [59]. PDK2 mRNA was still unaffected. Two hours
of swimming produced similar results as epinephrine
treatment in WAT in both lean and obese rats [59].
Combined with increased G3P synthesis via PEPCK,
more glyceroneogenesis allows increased re-esterification
of non-esterified fatty acids into TAG from lipolysis, while
glucose oxidation is reduced in these adipocytes [58].
With a major role in glucose clearance and fat synthe-
sis/storage, up-regulation of PDK4 during exercise, epi-
nephrine and TZD treatment leading to PDC inhibition,
promotes energy storage in WAT. More work is needed
for elucidating the transcriptional pathways involved in
PDK4 up-regulation in WAT [60].
PDK4 and metabolic flexibility in heart
Metabolic inflexibility always accompanies cardiomyop-
athy, particularly during ischemia, and may even cause
heart failure [41]. Failure to oxidize enough carbohydrate
to meet energy demands is an important reason for car-
diac inefficiency. This can be demonstrated by cardiac-
specific overexpression of PDK4, which is sufficient to
cause a loss of metabolic flexibility and exacerbate car-
diomyopathy [61]. Overexpression of PDK4 in heart with
a transgenic mice model was associated with a decrease
in glucose catabolism and a corresponding increase infatty acid oxidation. This transgenic model also expressed
a constitutively active form of the phosphatase calcineurin,
and thus caused hypertrophy in cardiomyocyte fibrosis
and a striking increase in mortality [61].
In mice that were fed a high fat diet for 10 days, the car-
diac carbohydrate oxidation markedly decreased, with
up-regulation of PDK4 activity. The high fat diet induced
cardiac metabolic alterations through the eukaryotic initi-
ation factor 4E (eIF4E)/cyclin D1/E2F1/PDK4 pathway [62].
During moderately severe ischemia, free fatty acids are
the primary fuel in mitochondrial oxidation [43]. While
glycolysis is still active and glucose is used for lactate
production to yield ATP, independent of oxygen, the in-
activation of PDC facilitates fatty acid use. Ischemia
causes pyruvate to be converted to lactate, thereby in-
creasing the acidification within the myocardium [41].
Thus inhibition of PDK activity by DCA is vital to increase
the ATP production as well as the Ca2+ uptake, and use of
the combination of glucose-insulin-K+ or fatty acid oxida-
tion inhibitors are also beneficial [41].
Angiotensin II (Ang II), the main effector in the renin
angiotensin system in heart failure, can induce marked
cardiac insulin resistance, leading to the cardiac metabolic
switch from glucose to fatty acid oxidation, producing
metabolic inflexibility and cardiac inefficiency [63]. PDK4
is highly expressed in this Ang II induced hypertrophy
model and deletion of PDK4 prevents the Ang II induced
reduction in glucose oxidation and prevents diastolic dys-
function [63]. Inhibition of PDK4 activity has become a
new therapeutic strategy against heart disease [41].
PDK and metabolic flexibility in the central nervous system
The brain also takes advantage of glucose oxidation as the
primary energy source. Cultured astrocytes expressed more
PDK2 and PDK4 compared to neurons, consistent with
the lower PDH activity and higher lactate production dis-
played by cultured astrocytes [64]. There is accumulating
evidence that alterations in PDKs activity are linked to the
development of several neurological disorders. For in-
stance, Alzheimer’s disease was associated with dysfunc-
tion in PDH activity and glucose metabolism [65]. Brain
aging is associated with reduced PDK1 and PDK2 mRNA
in the cerebellum and elevated PDK2 mRNA in the hip-
pocampus and cerebral cortex [66], and PDK2 mRNA up-
regulation was involved in glioblastoma [67].
Hypothalamic neurons are sensitive to nutritional sig-
nals and can regulate energy balance and glucose homeo-
stasis. However, the underlying complex mechanisms are
still not completely understood. Recent studies on mice
fasted for 48 h revealed a gene expression profile in hypo-
thalamus consistent with reduced glucose utilization and
increased lipid oxidation, including elevated PDK4mRNA,
consistent with the results in skeletal muscle, liver, heart
and kidney [68]. The up-regulation of PDK4 was also
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6 h, reflecting an attempt to conserve energy during neo-
natal food deprivation [69]. This also indicates that the
neonatal brain is not spared from glucose restriction dur-
ing energy crisis, but instead the neonatal brain can use
ketones derived from fatty acid metabolism as the major
source of energy [69]. However, only limited studies are
reported for PDK’s effect on hypothalamic energy balance.
More research is expected.
PDK and metabolic flexibility in other tissues
Pancreatic islets
In murine pancreatic β cells, both high fatty acid and
high glucose treatment increased PDK activity and de-
creased PDH activity. Palmitate up-regulated mRNA ex-
pression of PDK1, PDK2 and PDK4, while high glucose
increased PDK1, PDK2 mRNA but reduced PDK4
mRNA [70], suggestive of different transcriptional regu-
lation. Thus the induction of PDK expression by both
glucose and fat accompanies the decline in β cell metab-
olism flexibility during the progression from obesity to
T2D [70].
Chronic exposure to hyperglycemic conditions results
in glucotoxicity in β cells. Glucotoxicity impairs glucose
simulated insulin secretion (GSIS), contributing to the
development of T2D. Metabolomic analysis of β cells
after exposure to high glucose (25 mM for 20 h) re-
vealed an increase in glucose and decrease in fatty acids
during GSIS, but no significant changes in PDK2 protein
[71]. Similar research on insulinoma E (INS-1E) β cell
lines showed an increase in PDC E1α subunit phosphor-
ylation during high glucose treatment (50 mM for 48 h).
Knockdown of PDK1 and PDK3 led to a marked reduc-
tion in PDC inactivation. However, the PDC inactivation
was not associated with altered GSIS [72]. It is possible
that PDC activity in INS-1E β cells is in excess and there-
fore lowering its activity is of little consequence. Prolactin
can also induce GSIS in INS-1E cell lines by suppression
of PDKs and increased PDC activity, suggestive of a novel
role for lactogens in diabetes treatment [73]. As the most
important organ involved in the pathogenesis of T2D,
more research on metabolic flexibility in pancreatic β cells
is needed.
Cancer cells
Cancer cells have a unique way to acquire energy, termed
the Warburg effect. They utilize increased glycolysis and
suppress mitochondrial glucose oxidation to provide energy
with a proliferative advantage, conducive to apoptosis
resistance and even increased angiogenesis [74]. In low
nutrient conditions, the Warburg effect was enhanced
through a mechanism involving reactive oxygen species
(ROS)/AMPK- dependent activation of PDK [75,76].
PDK1 and PDK3 are the main isoforms related to theWarburg effect [41]. Thus inhibition of PDK with either
small interfering RNAs or orphan drugs, such as DCA,
can shift the metabolism of cancer cells from glycolysis
to glucose oxidation, and may provide a powerful ap-
proach to treat cancer [77].
Conclusions
As the major fuels for substrate oxidation to provide en-
ergy in mammals and human beings, glucose and fatty
acids can compete with each other at the level of the PDC.
PDC is normally active in most tissues in the well-fed
state. However, suppression of PDC activity by PDKs is
crucial to provide pyruvate and other three-carbon com-
pounds for glucose synthesis when glucose is in demand.
PDKs play a pivotal role in stable substrate switching and
energy homeostasis, which is known as metabolic flexibil-
ity, especially under some extreme nutrient conditions.
The alteration of PDKs expression, particularly PDK4,
has a tremendous influence on the health status of the or-
ganism. Inhibition of PDK4 can benefit specific tissues,
such as skeletal muscle, liver and heart, but up-regulation
of PDK4 is beneficial in white adipose tissue in obese and
insulin resistant rodents. This can be due to tissue-
specific physiology. Glucose is the major fuel source for
most tissues, inhibition of PDK4 thereby leading to PDC
activation and more glucose oxidation. As the major lipid
storage organ, white adipose tissue can take advantage of
fatty acids as an energy source, thus increased glyceroneo-
genesis caused by up-regulated PDK4 is beneficial. The
tissue-specific physiology also involves diverse transcrip-
tional regulation pathways, involving transcription factors
such as FoxO and PPARs (Figure 2).
Metabolic inflexibility, combined with abnormal PDKs
activity, is directly associated with many diseases, such as
T2D, obesity, metabolic disorders, cardiomyopathy, neuro-
logical disorders and several cancers. Future research on
PDC and PDKs regulation in various conditions and differ-
ent tissues will be beneficial to alleviate metabolic inflexibil-
ity and to provide possible therapies for numerous diseases.
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